Apotex Q1 FY27 IPO boosts balance sheet, Canada sales rise 11%

Apotex Inc. said on Thursday its initial public offering has strengthened its balance sheet, as the Canadian generic drugmaker reported an 11% increase in revenue in Canada for the first quarter of its fiscal year 2027.

The company did not disclose total revenue figures or other financial metrics in the slides accompanying the announcement. The IPO proceeds were allocated to reduce debt and improve liquidity, according to the presentation.

Apotex operates primarily in Canada and the United States, focusing on generic pharmaceuticals. The firm’s Canadian operations contributed to the reported revenue growth, though the company did not specify whether the increase was driven by volume, pricing, or market expansion.

The IPO, finalized earlier this year, was positioned as a strategic move to enhance Apotex’s financial flexibility amid rising competition in the generic drug sector. Analysts have noted that such capital-raising efforts are common in the industry as firms seek to invest in research, manufacturing, and acquisitions.

Apotex did not provide forward-looking guidance in the slides, and no additional details were available on the timing of the IPO or the allocation of proceeds beyond debt reduction and liquidity improvements.